These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30853812)

  • 1. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
    Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
    Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
    Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
    Heo YA; Syed YY
    Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
    Olsen J; Jensen KF; Olesen DS; Knoop A
    J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden.
    Valachis A; Sundqvist M; Carlsson L; Li B; Chiesa F; Uhde M; Sanglier T
    Future Oncol; 2019 Aug; 15(23):2733-2741. PubMed ID: 31306041
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
    Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
    De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
    Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial.
    Kaidarova D; Zhavrid E; Shatkovskaya O; Prokharau A; Akhmed N; Sembayev D; Rutzhanova Z; Ivankov A
    Cancer Treat Res Commun; 2024; 40():100817. PubMed ID: 38735220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
    Van den Nest M; Glechner A; Gold M; Gartlehner G
    Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review.
    Kolberg HC; Jackisch C; Hurvitz SA; Winstone J; Barham H; Hanes V; Courmier D
    Breast; 2021 Jun; 57():95-103. PubMed ID: 33799233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
    Jung KH; Ataseven B; Verrill M; Pivot X; De Laurentiis M; Al-Sakaff N; Lauer S; Shing M; Gligorov J; Azim HA
    Oncologist; 2018 Oct; 23(10):1137-1143. PubMed ID: 30018134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
    O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
    Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    Zambetti M; Montemurro F; Morandi P; Zamagni C; Brandes AA; Bisagni G; Cagossi K; Bengala C; Gori S; Iannacone C; Stell A; Gianni L
    Eur J Cancer; 2018 Dec; 105():61-70. PubMed ID: 30396014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.
    Duco MR; Murdock JL; Reeves DJ
    Ann Pharmacother; 2020 Mar; 54(3):254-261. PubMed ID: 31595774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
    Elsamany S; Elsisi GH; Hassanin F; Jafal M
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
    [No Abstract]   [Full Text] [Related]  

  • 18. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
    Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
    [No Abstract]   [Full Text] [Related]  

  • 19. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
    Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
    Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.